Interpreting Serological Tests in Diagnosing Autoimmune Liver Diseases

ABSTRACT

Autoimmune liver diseases (ALD) are characterized by immune-mediated injury of bile ducts or hepatocytes, thus including cholangiopathies such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis, and autoimmune hepatitis. Further, ALD variants manifesting with both hepatocellular and cholangiocellular damage are becoming more common. Serum autoantibodies, together with imaging and histology, are critical to the diagnostic process when ALD is suspected. Because an early diagnosis can influence prognosis, the development of sensitive and specific tests for serum autoantibodies should be a priority for researchers to ensure a more efficient noninvasive workup. Little prognostic value has been observed for any of the ALD serum hallmarks, and a vigorous effort to investigate new and old markers should therefore be undertaken in longitudinal studies as in the recent paradigm of PBC-specific antinuclear antibodies. We review herein the numerous ALD screening tests available in routine and specialized laboratories and comment on their significance in clinical practice.

Autoimmune hepatitis - primary biliary cirrhosis - primary sclerosing cholangitis - overlap syndromes - serum autoantibodies

REFERENCES

• 1 Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis.  Semin Liver Dis. 2005;  25 298-310
• 2 Beuers U, Rust C. Overlap syndromes.  Semin Liver Dis. 2005;  25 311-320
• 3 Cowling D C, Mackay I R, Taft L I. Lupoid hepatitis.  Lancet. 1956;  271 1323-1326
• 4 Krawitt E L. Autoimmune hepatitis.  N Engl J Med. 2006;  354 54-66
• 5 Homberg J C, Abuaf N, Bernard O et al.. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis.  Hepatology. 1987;  7 1333-1339
• 6 Alvarez F, Berg P A, Bianchi F B et al.. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.  J Hepatol. 1999;  31 929-938
• 7 Johnson P J, McFarlane I G. Meeting report: International Autoimmune Hepatitis Group.  Hepatology. 1993;  18 998-1005
• 8 Burgart L J, Batts K P, Ludwig J, Nikias G A, Czaja A J. Recent-onset autoimmune hepatitis: biopsy findings and clinical correlations.  Am J Surg Pathol. 1995;  19 699-708
• 9 Vergani D, Alvarez F, Bianchi F B et al.. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group.  J Hepatol. 2004;  41 677-683
• 10 Strassburg C P, Manns M P. Autoantibodies and autoantigens in autoimmune hepatitis.  Semin Liver Dis. 2002;  22 339-352
• 11 Hueber A J, Boxberger F, Ganslmayer M, Hahn E G. Antiphospholipid syndrome in combination with autoimmune hepatitis.  Eur J Gastroenterol Hepatol. 2005;  17 241-243
• 12 Muratori P, Muratori L, Guidi M et al.. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases.  Clin Exp Immunol. 2003;  132 473-476
• 13 Lyons R, Narain S, Nichols C, Satoh M, Reeves W H. Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease.  Ann NY Acad Sci. 2005;  1050 217-228
• 14 Strassburg C P, Alex B, Zindy F et al.. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases.  J Hepatol. 1996;  25 859-866
• 15 Strassburg C P, Manns M P. Antinuclear antibody (ANA) patterns in hepatic and extrahepatic autoimmune disease.  J Hepatol. 1999;  31 751
• 16 Czaja A J, Nishioka M, Morshed S A, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis.  Gastroenterology. 1994;  107 200-207
• 17 Czaja A J, Cassani F, Cataleta M, Valentini P, Bianchi F B. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis.  Hepatology. 1996;  24 1068-1073
• 18 Bottazzo G F, Florin-Christensen A, Fairfax A et al.. Classification of smooth muscle autoantibodies detected by immunofluorescence.  J Clin Pathol. 1976;  29 403-410
• 19 Gatselis N K, Georgiadou S P, Koukoulis G K et al.. Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C.  Aliment Pharmacol Ther. 2006;  24 1563-1573
• 20 Muratori P, Muratori L, Agostinelli D et al.. Smooth muscle antibodies and type 1 autoimmune hepatitis.  Autoimmunity. 2002;  35 497-500
• 21 Czaja A J. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis.  J Hepatol. 1999;  30 394-401
• 22 Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde K H. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen.  Lancet. 1987;  1 292-294
• 23 Teufel M, Niessen K H, Berg P A. Chronic active hepatitis in childhood with detection of liver-pancreas-specific autoantibodies.  Eur J Pediatr. 1983;  140 30-33
• 24 Wies I, Brunner S, Henninger J et al.. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis.  Lancet. 2000;  355 1510-1515
• 25 Herkel J, Heidrich B, Nieraad N et al.. Fine specificity of autoantibodies to soluble liver antigen and liver/pancreas.  Hepatology. 2002;  35 403-408
• 26 Ma Y, Okamoto M, Thomas M G et al.. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease.  Hepatology. 2002;  35 658-664
• 27 Baeres M, Herkel J, Czaja A J et al.. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics.  Gut. 2002;  51 259-264
• 28 Czaja A J, Donaldson P T, Lohse A W. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis.  Am J Gastroenterol. 2002;  97 413-419
• 29 Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders.  Clin Exp Immunol. 1973;  15 331-344
• 30 Muratori L, Lenzi M, Ma Y et al.. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease.  Gut. 1995;  37 406-412
• 31 Yamamoto A M, Cresteil D, Homberg J C, Alvarez F. Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera.  Gastroenterology. 1993;  104 1762-1767
• 32 Yamamoto A M, Johanet C, Duclos-Vallee J C et al.. A new approach to cytochrome CYP2D6 antibody detection in autoimmune hepatitis type-2 (AIH-2) and chronic hepatitis C virus (HCV) infection: a sensitive and quantitative radioligand assay.  Clin Exp Immunol. 1997;  108 396-400
• 33 Homberg J C, Abuaf N, Helmy-Khalil S et al.. Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies.  Hepatology. 1985;  5 722-727
• 34 Manns M P, Griffin K J, Sullivan K F, Johnson E F. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase.  J Clin Invest. 1991;  88 1370-1378
• 35 Manns M P, Vogel A. Autoimmune hepatitis, from mechanisms to therapy.  Hepatology. 2006;  43(suppl 1) S132-S144
• 36 Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens.  Hepatology. 2004;  39 1066-1074
• 37 Lenzi M, Manotti P, Muratori L et al.. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection.  Gut. 1995;  36 749-754
• 38 Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi F B. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis.  Gut. 1998;  42 721-726
• 39 Lapierre P, Hajoui O, Homberg J C, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis.  Gastroenterology. 1999;  116 643-649
• 40 Poralla T, Treichel U, Lohr H, Fleischer B. The asialoglycoprotein receptor as target structure in autoimmune liver diseases.  Semin Liver Dis. 1991;  11 215-222
• 41 Treichel U, Gerken G, Rossol S et al.. Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis.  J Hepatol. 1993;  19 55-63
• 42 Targan S R, Landers C, Vidrich A, Czaja A J. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis.  Gastroenterology. 1995;  108 1159-1166
• 43 Kaplan M M, Gershwin M E. Primary biliary cirrhosis.  N Engl J Med. 2005;  353 1261-1273
• 44 Prince M I, Chetwynd A, Craig W L, Metcalf J V, James O F. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.  Gut. 2004;  53 865-870
• 45 Mackay I R, Whittingham S, Fida S et al.. The peculiar autoimmunity of primary biliary cirrhosis.  Immunol Rev. 2000;  174 226-237
• 46 Gershwin M E, Ansari A A, Mackay I R et al.. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells.  Immunol Rev. 2000;  174 210-225
• 47 Invernizzi P, Crosignani A, Battezzati P M et al.. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis.  Hepatology. 1997;  25 1090-1095
• 48 Heathcote E J. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.  Hepatology. 2000;  31 1005-1013
• 49 Van de Water J, Cooper A, Surh C D et al.. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis.  N Engl J Med. 1989;  320 1377-1380
• 50 Kitami N, Komada T, Ishii H et al.. Immunological study of anti-M2 in antimitochondrial antibody-negative primary biliary cirrhosis.  Intern Med. 1995;  34 496-501
• 51 Mattalia A, Luttig B, Rosina F et al.. Persistence of autoantibodies against recombinant mitochondrial and nuclear pore proteins after orthotopic liver transplantation for primary biliary cirrhosis.  J Autoimmun. 1997;  10 491-497
• 52 Oertelt S, Rieger R, Selmi C et al.. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis.  Hepatology. 2007;  45 659-665
• 53 Joshi S, Cauch-Dudek K, Heathcote E J et al.. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis'.  Am J Gastroenterol. 2002;  97 999-1002
• 54 Neuberger J, Bradwell A R. Anti-mitochondrial antibodies in primary biliary cirrhosis.  J Hepatol. 2002;  37 712-716
• 55 Muratori L, Muratori P, Granito A et al.. The Western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis.  Dig Liver Dis. 2005;  37 108-112
• 56 Ishibashi H, Shimoda S, Gershwin M E. The immune response to mitochondrial autoantigens.  Semin Liver Dis. 2005;  25 337-346
• 57 Nishio A, Keeffe E B, Gershwin M E. Immunopathogenesis of primary biliary cirrhosis.  Semin Liver Dis. 2002;  22 291-302
• 58 Metcalf J V, Mitchison H C, Palmer J M et al.. Natural history of early primary biliary cirrhosis.  Lancet. 1996;  348 1399-1402
• 59 Invernizzi P, Podda M, Battezzati P M et al.. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis.  J Hepatol. 2001;  34 366-372
• 60 Muratori P, Muratori L, Ferrari R et al.. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis.  Am J Gastroenterol. 2003;  98 431-437
• 61 Rigopoulou E I, Davies E T, Pares A et al.. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis.  Gut. 2005;  54 528-532
• 62 Yang W H, Yu J H, Nakajima A et al.. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure'.  Clin Gastroenterol Hepatol. 2004;  2 1116-1122
• 63 Itoh S, Ichida T, Yoshida T et al.. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis.  J Gastroenterol Hepatol. 1998;  13 257-265
• 64 Miyachi K, Hankins R W, Matsushima H et al.. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study.  J Autoimmun. 2003;  20 247-254
• 65 Invernizzi P, Wesierska-Gadek J, Battezzati P M et al.. Prognostic value of autoantibodies against proteins of nuclear pore complexes (anti-NPCs) in early primary biliary cirrhosis (PBC).  J Hepatol. 2004;  40 159-160. Abstract
• 66 Wesierska-Gadek J, Penner E, Battezzati P M et al.. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis.  Hepatology. 2006;  43 1135-1144
• 67 Nakamura M, Shimizu-Yoshida Y, Takii Y et al.. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.  J Hepatol. 2005;  42 386-392
• 68 Nakamura M, Kondo H, Mori T et al.. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis.  Hepatology. 2007;  45 118-127
• 69 Dickson E R, Grambsch P M, Fleming T R, Fisher L D, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making.  Hepatology. 1989;  10 1-7
• 70 Heathcote J. Autoimmune cholangitis.  Gut. 1997;  40 440-442
• 71 Czaja A J, Carpenter H A, Santrach P J, Moore S B. Autoimmune cholangitis within the spectrum of autoimmune liver disease.  Hepatology. 2000;  31 1231-1238
• 72 Lee Y M, Kaplan M M. Primary sclerosing cholangitis.  N Engl J Med. 1995;  332 924-933
• 73 Cullen S N, Chapman R W. The medical management of primary sclerosing cholangitis.  Semin Liver Dis. 2006;  26 52-61
• 74 Lazaridis K N, Gores G J. Primary sclerosing cholangitis and cholangiocarcinoma.  Semin Liver Dis. 2006;  26 42-51
• 75 Worthington J, Cullen S, Chapman R. Immunopathogenesis of primary sclerosing cholangitis.  Clin Rev Allergy Immunol. 2005;  28 93-103
• 76 Aoki C A, Bowlus C L, Gershwin M E. The immunobiology of primary sclerosing cholangitis.  Autoimmun Rev. 2005;  4 137-143
• 77 Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis.  Semin Liver Dis. 1991;  11 31-39
• 78 Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer.  Semin Liver Dis. 2006;  26 31-41
• 79 Wiencke K, Spurkland A, Schrumpf E, Boberg K M. Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles.  Hepatology. 2001;  34 625-630
• 80 O'Mahony C A, Vierling J M. Etiopathogenesis of primary sclerosing cholangitis.  Semin Liver Dis. 2006;  26 3-21
• 81 Mayer L. Redefining autoimmunity.  Gastroenterology. 2003;  125 1574
• 82 Hamano H, Kawa S, Horiuchi A et al.. High serum IgG4 concentrations in patients with sclerosing pancreatitis.  N Engl J Med. 2001;  344 732-738
• 83 Mendes F D, Jorgensen R, Keach J et al.. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis.  Am J Gastroenterol. 2006;  101 2070-2075
• 84 Levy C, Lindor K D. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis.  Semin Liver Dis. 2006;  26 22-30
• 85 Mieli-Vergani G, Vergani D. Immunological liver diseases in children.  Semin Liver Dis. 1998;  18 271-279
• 86 Gross W L, Ludemann G, Kiefer G, Lehmann H. Anticytoplasmic antibodies in Wegener's granulomatosis.  Lancet. 1986;  1 806
• 87 Jenne D E, Tschopp J, Ludemann J, Utecht B, Gross W L. Wegener's autoantigen decoded.  Nature. 1990;  346 520
• 88 Peen E, Sundqvist T, Skogh T. Leucocyte activation by anti-lactoferrin antibodies bound to vascular endothelium.  Clin Exp Immunol. 1996;  103 403-407
• 89 Seibold F, Weber P, Klein R, Berg P A, Wiedmann K H. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis.  Gut. 1992;  33 657-662
• 90 Duerr R H, Targan S R, Landers C J et al.. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis.  Gastroenterology. 1991;  100 1385-1391
• 91 Mulder A H, Broekroelofs J, Horst G et al.. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates.  Clin Exp Immunol. 1994;  95 490-497
• 92 Terjung B, Herzog V, Worman H J et al.. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins.  Hepatology. 1998;  28 332-340
• 93 Terjung B, Worman H J. Anti-neutrophil antibodies in primary sclerosing cholangitis.  Best Pract Res Clin Gastroenterol. 2001;  15 629-642
• 94 Terjung B, Spengler U, Sauerbruch T, Worman H J. “Atypical p-ANCA” in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines.  Gastroenterology. 2000;  119 310-322
• 95 Roozendaal C, de Jong M A, van den Berg A P et al.. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases.  J Hepatol. 2000;  32 734-741
• 96 Angulo P, Peter J B, Gershwin M E et al.. Serum autoantibodies in patients with primary sclerosing cholangitis.  J Hepatol. 2000;  32 182-187
• 97 Xu B, Broome U, Ericzon B G, Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6.  Gut. 2002;  51 120-127
• 98 Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage.  Cancer Sci. 2004;  95 930-935
• 99 Naor D, Nedvetzki S. CD44 in rheumatoid arthritis.  Arthritis Res Ther. 2003;  5 105-115
• 100 Beuers U. Hepatic overlap syndromes.  J Hepatol. 2005;  42(suppl 1) S93-S99
• 101 Czaja A J. The variant forms of autoimmune hepatitis.  Ann Intern Med. 1996;  125 588-598
• 102 Kaya M, Angulo P, Lindor K D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system.  J Hepatol. 2000;  33 537-542
• 103 Chazouilleres O. Diagnosis of primary sclerosing cholangitis-autoimmune hepatitis overlap syndrome: to score or not to score'.  J Hepatol. 2000;  33 661-663
• 104 Gregorio G V, Portmann B, Karani J et al.. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study.  Hepatology. 2001;  33 544-553
• 105 Vignali D A. Multiplexed particle-based flow cytometric assays.  J Immunol Methods. 2000;  243 243-255